King's College London
Division of University of London
Latest From King's College London
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.
Bristol can buy out Galecto any time up to 60 days after the completion of a Phase Ib study of an inhalable drug candidate for idiopathic pulmonary fibrosis. The deal follows just weeks after FDA approved the first two drug therapies for IPF.
Drug development is a costly and challenging process, with a high attrition rate. Imanova Ltd., based in London, is a translational imaging center with an aim to improve success rates by using molecular imaging techniques to provide early information in clinical studies to support development decisions.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.